| First Author | Kim D | Year | 2018 |
| Journal | Acta Neuropathol Commun | Volume | 6 |
| Issue | 1 | Pages | 32 |
| PubMed ID | 29703245 | Mgi Jnum | J:313205 |
| Mgi Id | MGI:6791623 | Doi | 10.1186/s40478-018-0538-9 |
| Citation | Kim D, et al. (2018) D409H GBA1 mutation accelerates the progression of pathology in A53T alpha-synuclein transgenic mouse model. Acta Neuropathol Commun 6(1):32 |
| abstractText | Heterozygous mutations in glucocerebrosidase 1 (GBA1) are a major genetic risk factor for Parkinson's disease and Dementia with Lewy bodies. Mutations in GBA1 leads to GBA1 enzyme deficiency, and GBA1-associated parkinsonism has an earlier age of onset and more progressive parkinsonism. To investigate a potential influence of GBA1 deficiency caused by mutations in GBA1 on the disease progression of PD, GBA1 mice carrying D409H knock-in mutation were crossbred with the human A53T (hA53T) alpha-synuclein transgenic mice. Here, we show that GBA1 enzyme activity plays a significant role in the hA53T alpha-synuclein induced alpha-synucleinopathy. The expression of D409H GBA1 markedly shortens the lifespan of hA53T alpha-synuclein transgenic mice. Moreover, D409H GBA1 expression exacerbates the formation of insoluble aggregates of alpha-synuclein, glial activation, neuronal degeneration, and motor abnormalities in the hA53T alpha-synuclein transgenic mice. Interestingly, the expression of D409H GBA1 results in the loss of dopaminergic neurons in the substantia nigra pars compacta of hA53T transgenic mice. Taken together, these results indicate that GBA1 deficiency due to D409H mutation affects the disease onset and course in hA53T alpha-synuclein transgenic mice. Therefore, strategies aimed to maintain GBA1 enzyme activity could be employed to develop an effective novel therapy for GBA1 linked-PD and related alpha-synucleinopathies. |
